Neuropilin-1 is expressed by breast cancer stem-like cells and is linked to NF-κB activation and tumor sphere formation

Biochemical and Biophysical Research Communications

Volumn 425, Issue 4, 2012, Pages 775-780

  Glinka, Yelena ^a   Mohammed, Nada ^a   Subramaniam, Venkateswaran ^a   Jothy, Serge ^a,b,c   Prud'homme, Gérald J ^a,b,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast cancer; Cancer stem cells; Mammosphere; Neuropilin; NF kappaB; Tranilast

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUROPILIN 1; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANILAST;

ARTICLE; BREAST CANCER; CANCER STEM CELL; CARCINOGENICITY; CELL POPULATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASTIC STEM CELLS; NEUROPILIN-1; NF-KAPPA B; ORTHO-AMINOBENZOATES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SPHEROIDS, CELLULAR;

EID: 84865992234     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.07.151     Document Type: Article

References (38)

1. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
2. O'Brien C.A., Kreso A., Dick J.E. Cancer stem cells in solid tumors: an overview. Semin. Radiat. Oncol. 2009, 19:71-77.
3. Prud'homme G.J. Cancer stem cells and novel targets for antitumor strategies. Curr. Pharm. Des. 2012, 18:2838-2849.
4. Visvader J.E., Lindeman G.J. Cancer stem cells: current status and evolving complexities. Cell. Stem. Cell 2012, 10:717-728.
5. Prud'homme G.J., Glinka Y., Toulina A., et al. Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS One 2010, 5:e13831.
6. Rogosnitzky M., Danks R., Kardash E. Therapeutic potential of tranilast, an anti-allergy drug, in proliferative disorders. Anticancer Res. 2012, 32:2471-2478.
7. Barhoover B.A., Hall J.M., Greenlee W.F., et al. Aryl hydrocarbon receptor regulates cell cycle progression in human breast cancer cells via a functional interaction with cyclin-dependent kinase 4. Mol. Pharmacol. 2010, 77:195-201.
8. Casado F.L., Singh K.P., Gasiewicz T.A. Aryl hydrocarbon receptor activation in hematopoietic stem/progenitor cells alters cell function and pathway-specific gene modulation reflecting changes in cellular trafficking and migration. Mol. Pharmacol. 2011, 80:673-682.
9. Matthews J., Gustafsson J.A. Estrogen receptor and aryl hydrocarbon receptor signaling pathways. Nucl. Recept. Signal. 2004, 4:e016.
10. Ruby C.E., Leid M., Kerkvliet N.I. 2,3,7,8-Tetrachlorodibenzo-p-dioxin suppresses tumor necrosis factor-alpha and anti-CD40-induced activation of NF-kappaB/Rel in dendritic cells: p50 homodimer activation is not affected. Mol. Pharmacol. 2002, 62:722-728.
11. Ponti D., Costa A., Zaffaroni N., et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005, 65:5506-5511.
12. Grimshaw M.J., Cooper L., Papazisis K., et al. Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res. 2008, 10:R52.
13. Cioce M., Gherardi S., Viglietto G., et al. Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like- and early progenitor-targeting drugs. Cell Cycle 2010, 9:2878-2887.
14. Park S.Y., Lee H.E., Li H., et al. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin. Cancer Res. 2010, 16:876-887.
15. Zhou J., Zhang H., Gu P., et al. NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res. Treat. 2008, 111:419-427.
16. Hamerlik P., Lathia J.D., Rasmussen R., et al. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J. Exp. Med. 2012, 209:507-520.
17. Beck B., Driessens G., Goossens S., et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 2011, 478:399-403.
18. Rizzolio S., Tamagnone L. Multifaceted role of neuropilins in cancer. Curr. Med. Chem. 2011, 18:3563-3575.
19. Chakrabarti R., Subramaniam V., Abdalla S., et al. Tranilast inhibits the growth and metastasis of mammary carcinoma. Anti-Cancer Drugs 2009, 20:334-345.
20. Charafe-Jauffret E., Ginestier C., Iovino F., et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009, 69:1302-1313.
21. Croker A.K., Goodale D., Chu J., et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J. Cell Mol. Med. 2009, 13:2236-2252.
22. Sheridan C., Kishimoto H., Fuchs R.K., et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006, 8:R59.
23. Ricardo S., Vieira A.F., Gerhard R., et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J. Clin. Pathol. 2011, 64:937-946.
24. Glinka Y., Stoilova S., Mohammed N., et al. Neuropilin-1 exerts co-receptor function for TGF-beta-1 on the membrane of cancer cells and enhances responses to both latent and active TGF-beta. Carcinogenesis 2011, 32:613-621.
25. Timoshenko A.V., Rastogi S., Lala P.K. Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells. Br. J. Cancer 2007, 97:1090-1098.
26. Bassères D.S., Baldwin A.S. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006, 25:6817-6830.
27. Shostak K., Chariot A. NF-κB, stem cells and breast cancer: the links get stronger. Breast Cancer Res. 2011, 13:214.
28. Hinohara K., Kobayashi S., Kanauchi H., et al. ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in humanbreast cancer. Proc. Natl. Acad. Sci. USA 2012, 109:6584-6589.
29. Zachary I.C. How neuropilin-1 regulates receptor tyrosine kinase signalling: the knows and known unknowns. Biochem. Soc. Trans. 2011, 39:1583-1591.
30. Cao Y., Wang L., Nandy D., et al. Neuropilin-1 upholds dedifferentiation and propagation phenotypes of renal cellcarcinoma cells by activating Akt and sonic hedgehog axes. Cancer Res. 2008, 68:8667-8672.
31. Spiecker M., Lorenz I., Marx N., et al. Tranilast inhibits cytokine-induced nuclear factor kappaB activation in vascular endothelial cells. Mol. Pharmacol. 2002, 62:856-863.
32. Adachi T., Fukuda K., Kondo Y., et al. Inhibition by tranilast of the cytokine-induced expression of chemokines and the adhesion molecule VCAM-1 in human corneal fibroblasts. Invest. Ophthalmol. Vis. Sci. 2010, 51:3954-3960.
33. Suzawa H., Kikuchi S., Ichikawa K., et al. Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines and PGE2 from human monocytes-macrophages. Jpn. J. Pharmacol. 1992, 60:85-90.
34. Platten M., Ho P.P., Youssef S., et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2005, 310:850-855.
35. Glinka Y., Prud'homme G.J. Neuropilin-1 is a receptor for transforming growth factor beta-1, activates its latent form, and promotes regulatory T cell activity. J. Leukoc. Biol. 2008, 84:302-310.
36. Hu B., Guo P., Bar-Joseph I., et al. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene 2007, 26:5577-5586.
37. Pellet-Many C., Frankel P., Evans I.M., et al. Neuropilin-1 mediates PDGF stimulation of vascular smooth muscle cell migration and signalling via p130Cas. Biochem. J. 2011, 435:609-618.
38. West D.C., Rees C.G., Duchesne L., et al. Interactions of multiple heparin binding growth factors with neuropilin-1 and potentiation of the activity of fibroblast growth factor-2. J. Biol. Chem. 2005, 280:13457-13464.